Healthcare / Medical Instruments & SuppliesKOSDAQ
$2825.00
-60.00 (-2.08%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-5.3B · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$90.4B
P/E
10.3x
↓EV/EBITDA
6.0x
↓ROE
6.6%
↑Gross Margin
25.3%
↓Debt/Equity
0.30
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+6.7%
FCF CAGR
—
FCF margin
-4.0%
FCF / Net income
-0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $130.34B · net income $8.66B · FCF $-5.26B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $130.34B | $130.34B | $131.82B | $120.16B | $107.23B |
| Net Income | $8.66B | $8.66B | $2.24B | $4.17B | $4.24B |
| EBITDA | $21.02B | $21.02B | $18.52B | $13.11B | $11.36B |
| EPS | 275.00 | 275.00 | 40.00 | 186.00 | 1893.50 |
| Gross Margin | 25.3% | 25.3% | 21.7% | 21.0% | 20.7% |
| Operating Margin | 10.0% | 10.0% | 9.0% | 7.1% | 5.8% |
| Net Margin | 6.6% | 6.6% | 1.7% | 3.5% | 4.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.30 | 0.30 | 0.43 | 0.69 | 0.64 |
| Current Ratio | 1.71 | 1.71 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-5.26B | $-5.26B | $6.45B | $-9.40B | $-20.30B |
| Returns | |||||
| ROE | 6.6% | 6.6% | 2.1% | 6.1% | 6.5% |
| Valuation | |||||
| P/E | 10.27 | 10.27 | — | — | — |
| EV/EBITDA | 5.99 | 5.99 | — | — | — |
| P/B | 0.68 | 0.68 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | -1.1% | -1.1% | 9.7% | 12.1% | — |
| EPS Growth | 587.5% | 587.5% | -78.5% | -90.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-3.0%
EPS terminal req.
$250.67
Spread vs growth
590.5%
5Y implied EPS CAGR
2.0%
EPS terminal req.
$303.31
Spread vs growth
585.5%
10Y implied EPS CAGR
5.9%
EPS terminal req.
$488.49
Spread vs growth
581.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.3%
Start / end P/E
112.6x → 10.3x
EPS bridge
40.00 → 275.00
Residual
-533.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.